Westwood Holdings Group Inc. Decreases Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Westwood Holdings Group Inc. decreased its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 67.2% during the first quarter, Holdings Channel.com reports. The fund owned 14,859 shares of the company’s stock after selling 30,473 shares during the quarter. Westwood Holdings Group Inc.’s holdings in CRISPR Therapeutics were worth $1,013,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of CRSP. Blue Trust Inc. purchased a new position in shares of CRISPR Therapeutics in the fourth quarter valued at about $32,000. Bourgeon Capital Management LLC increased its position in shares of CRISPR Therapeutics by 1,000.0% during the fourth quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock valued at $34,000 after buying an additional 500 shares during the period. Riggs Asset Managment Co. Inc. increased its position in shares of CRISPR Therapeutics by 66.7% during the first quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock valued at $34,000 after buying an additional 200 shares during the period. Principal Securities Inc. purchased a new position in shares of CRISPR Therapeutics during the fourth quarter valued at about $41,000. Finally, NBC Securities Inc. increased its position in shares of CRISPR Therapeutics by 257.6% during the first quarter. NBC Securities Inc. now owns 608 shares of the company’s stock valued at $41,000 after buying an additional 438 shares during the period. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Analysts Set New Price Targets

CRSP has been the topic of several research analyst reports. Robert W. Baird boosted their price target on shares of CRISPR Therapeutics from $46.00 to $52.00 and gave the company a “neutral” rating in a research report on Thursday, May 9th. JMP Securities reiterated a “market outperform” rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, May 9th. Cantor Fitzgerald reiterated a “neutral” rating on shares of CRISPR Therapeutics in a research report on Thursday, May 9th. Guggenheim reissued a “neutral” rating on shares of CRISPR Therapeutics in a research note on Friday, June 28th. Finally, Oppenheimer dropped their price objective on shares of CRISPR Therapeutics from $102.00 to $95.00 and set an “outperform” rating on the stock in a research note on Friday, May 10th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, CRISPR Therapeutics has a consensus rating of “Hold” and a consensus price target of $76.67.

Insider Buying and Selling at CRISPR Therapeutics

In other news, COO Julianne Bruno sold 3,366 shares of the stock in a transaction on Friday, June 21st. The shares were sold at an average price of $56.09, for a total value of $188,798.94. Following the completion of the sale, the chief operating officer now directly owns 6,745 shares of the company’s stock, valued at $378,327.05. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.10% of the stock is owned by corporate insiders.

CRISPR Therapeutics Trading Down 6.8 %

CRSP stock traded down $3.74 during midday trading on Friday, reaching $51.11. 2,557,314 shares of the company’s stock traded hands, compared to its average volume of 1,300,299. CRISPR Therapeutics AG has a 52-week low of $37.55 and a 52-week high of $91.10. The stock has a market cap of $4.34 billion, a P/E ratio of -18.79 and a beta of 1.70. The stock’s 50-day moving average is $57.20 and its 200 day moving average is $63.25.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Wednesday, May 8th. The company reported ($1.43) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.08). The business had revenue of $0.50 million for the quarter, compared to analyst estimates of $25.53 million. During the same period in the prior year, the company posted ($0.67) earnings per share. The company’s revenue was down 99.5% compared to the same quarter last year. As a group, research analysts expect that CRISPR Therapeutics AG will post -5.52 EPS for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.